[{"id":"647b1a25-385e-4dd4-87ce-8fee2a316c5b","acronym":"PM8002-B004C-TNBC-R","url":"https://clinicaltrials.gov/study/NCT05918133","created_at":"2023-06-26T14:09:06.723Z","updated_at":"2025-02-25T16:27:29.863Z","phase":"Phase 1/2","brief_title":"A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC","source_id_and_acronym":"NCT05918133 - PM8002-B004C-TNBC-R","lead_sponsor":"Biotheus Inc.","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • pumitamig (BNT327)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 10/30/2026","primary_completion_date":" 10/30/2026","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2024-12-03"}]